Launch Tech Co Ltd Stock
Price
Target price
?
?
-1.920%
-0.015
-1.920%
-
08:32 / Stuttgart Stock Exchange
WKN: A0M4VZ / Name: Launch / Stock / Machinery, Equipment & Components / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Launch
sharewise wants to provide you with the best news and tools for Launch, so we directly link to the best financial data sources.
Financials
News
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
Tonix Pharmaceuticals (NASDAQ:TNXP) is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing
Applied Aerospace & Defense Q2 Earnings Call Highlights
Key Points
- Interested in Applied Aerospace & Defense, Inc.? Here are five stocks we like better.
- Record second-quarter results: Revenue rose 47.4% year over year to $167.3 million, while
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances
Key Points
- Interested in Compass Pathways PLC Sponsored ADR? Here are five stocks we like better.
- Compass Pathways expects to complete its FDA application for COMP360 in the fourth quarter of
Mineralys Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Mineralys Therapeutics, Inc.? Here are five stocks we like better.
- Mineralys is preparing for a potential lorundrostat launch ahead of the FDA’s Dec. 22 PDUFA target
Rocket Lab’s Record Quarter Still Left Investors Waiting on Neutron
Key Points
- Interested in Rocket Lab Corporation? Here are five stocks we like better.
- Rocket Lab reported record Q2 revenue and backlog, supported by growth in Space Systems and new launch
Autolus Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in Autolus Therapeutics PLC Sponsored ADR? Here are five stocks we like better.
- AUCATZYL sales accelerated: Second-quarter net product revenue rose to $45.7 million, up
Rocket Lab Q2 Earnings Call Highlights
Key Points
- Interested in Rocket Lab Corporation? Here are five stocks we like better.
- Record growth and backlog: Rocket Lab reported Q2 revenue of $234 million, up 62% year over year, and ended
NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles
Key Points
- Interested in NRx Pharmaceuticals, Inc.? Here are five stocks we like better.
- NRx Pharmaceuticals completed the FDA’s first-cycle review of its preservative-free ketamine ANDA, with
Redwire Q2 Earnings Call Highlights
Key Points
- Interested in Redwire Corporation? Here are five stocks we like better.
- Record quarterly performance: Redwire’s Q2 revenue rose 89.6% year over year to $117.1 million, while gross
Karman Q2 Earnings Call Highlights
Key Points
- Interested in Karman Holdings Inc.? Here are five stocks we like better.
- Record results and raised guidance: Second-quarter revenue increased 58% year over year to $182 million, while
Artivion Q2 Earnings Call Highlights
Key Points
- Interested in Artivion, Inc.? Here are five stocks we like better.
- Artivion’s Q2 revenue rose 9% to $125.8 million on a constant-currency basis, driven by 12% growth in stent grafts
GoodRx Q2 Earnings Call Highlights
Key Points
- Interested in GoodRx Holdings, Inc.? Here are five stocks we like better.
- GoodRx raised its full-year outlook after reporting Q2 revenue of $200.4 million and adjusted EBITDA of $63.7
Alpha Teknova Q2 Earnings Call Highlights
Alpha Teknova (NASDAQ:TKNO) reported second-quarter revenue growth of 18% from a year earlier, surpassing $12 million for its highest quarterly revenue in the company’s 30-year history. The company
Energy Recovery Q2 Earnings Call Highlights
Key Points
- Interested in Energy Recovery, Inc.? Here are five stocks we like better.
- Middle East desalination growth remains delayed: Energy Recovery’s pipeline is strong and extends several
United Therapeutics Q2 Earnings Call Highlights
Key Points
- Interested in United Therapeutics Corporation? Here are five stocks we like better.
- Second-quarter revenue was approximately $783 million, essentially flat sequentially, as
Ionis Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Ionis Pharmaceuticals, Inc.? Here are five stocks we like better.
- Second-quarter revenue rose to $268 million, with commercial revenue reaching $119 million, driven
A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
Key Points
- Interested in SpaceX? Here are five stocks we like better.
- SpaceX shares have fallen below their $135 IPO price, erasing over $1 trillion in implied market value amid concerns about
Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer
Key Points
- Interested in Celcuity, Inc.? Here are five stocks we like better.
- Celcuity won full FDA approval for gedatolisib, now branded REVTORPYK, in a specific advanced breast cancer
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Key Points
- Interested in Vera Therapeutics, Inc.? Here are five stocks we like better.
- Vera Therapeutics won accelerated FDA approval for TRUTAKNA (atacicept-vymj) to treat adults with primary
Rocket Lab Defies Gravity With $8B Buyout
Key Points
- Interested in Rocket Lab Corporation? Here are five stocks we like better.
- Rocket Lab agreed to acquire Iridium Communications in an estimated $8 billion cash-and-stock deal
Rocket Lab's NASA Win Tests Key Support After Sharp Pullback
Key Points
- Interested in Rocket Lab Corporation? Here are five stocks we like better.
- Rocket Lab’s latest NASA selection for three dedicated Electron launches reinforces its credibility with
The Biggest Opportunity From SpaceX’s IPO May Surprise You
Key Points
- Interested in Redwire Corporation? Here are five stocks we like better.
- The SpaceX IPO is more than four times oversubscribed, leaving an estimated $225 billion in sidelined capital to
Alnylam Pharmaceuticals Unveils 2030 Targets, Betting on AMVUTTRA and Pipeline Readouts
Key Points
- Interested in Alnylam Pharmaceuticals, Inc.? Here are five stocks we like better.
- Alnylam set new 2030 goals targeting 25% annual revenue growth and a 30% non-GAAP operating margin
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
Key Points
- Interested in Arvinas, Inc.? Here are five stocks we like better.
- Arvinas is narrowing its pipeline focus after the first PROTAC approval, concentrating internal investment on
Before the IPO: 4 Companies That Rewarded Investors Who Got In Early
Key Points
- Interested in Starfighters Space, Inc.? Here are five stocks we like better.
- Weiss Ratings analyst Chris Graebe argues the largest IPO gains go to investors who enter companies at the